Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4037/aacnacc2023957 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The anticoagulant effects of milvexian, a novel small molecule factor XIa inhibitor, are neutralized by activated prothrombin complex concentrates and recombinant factor VIIa in human plasma and whole blood .
Res Pract Thromb Haemost
November 2024
Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.
Background: The development of anticoagulants that provide antithrombotic efficacy without a concomitant bleeding risk remains an unmet clinical need in thrombosis. Although direct oral anticoagulants (DOACs) have a reduced incidence of major bleeding compared with warfarin, they still carry a bleeding risk, resulting in a suboptimal therapeutic index. Epidemiologic data suggest that inhibiting activated factor XI (FXIa) may offer an improved safety profile with respect to bleeding risk compared with current-generation DOACs.
View Article and Find Full Text PDFEvaluation of coagulation by thromboelastography and a velocity curve in dogs with parvoviral enteritis.
Vet Med (Praha)
October 2024
Department of Internal Medicine, Faculty of Veterinary Medicine, Bursa Uludag University, Bursa, Turkey.
Article Synopsis
- The study investigates the coagulation status of dogs with canine parvoviral enteritis (CPE), a severe condition that can lead to high mortality due to systemic inflammation and multi-organ dysfunction.
- It involved 21 dogs diagnosed with CPE and 5 healthy controls, using thromboelastography (TEG) to analyze coagulation, showing significant differences in reaction times and clot dissolution rates.
- The findings suggest that TEG-derived velocity curve (v-curve) parameters could be a better method to assess coagulation in CPE cases, offering new insights for diagnosis and treatment strategies.
The factor XI/XIa antibody abelacimab combined with enoxaparin inhibits filter clotting in hemodialysis circuits ex vivo.
J Thromb Thrombolysis
December 2024
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria.
Drugs targeting factor XI may offer an alternative to heparin for preventing blood clotting in extracorporeal circulation. We investigated the effects of abelacimab, a novel monoclonal antibody targeting factor XI. We collected whole blood samples into two bags (each 240 ml, control group: enoxaparin 1.
View Article and Find Full Text PDFA novel γ-chain mutation p.Asp318His in a Chinese family with dysfibrinogenemia.
Blood Coagul Fibrinolysis
December 2024
Department of Clinical Laboratory, The Affiliated Hospital of Jiaxing University (The First Hospital of Jiaxing), Jiaxing, China.
Background: Congenital dysfibrinogenemia is characterized by reduced fibrinogen activity, but normal immunoreactive fibrinogen levels. Here, we present a novel case with an elevated risk of thrombosis.
Methods: Coagulation assays, gene analysis, in silico tools, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), fibrin polymerization, thrombin generation assay, and electron microscopy scanning were utilized to elucidate the pathogenic mechanism.
Platelet Contribution and Endothelial Activation and Stress Index-Potential Mortality Predictors in Traumatic Brain Injury.
Int J Mol Sci
July 2024
Department of Anesthesiology and Intensive Care II, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Coagulopathy and traumatic brain injury (TBI) are complexly intertwined. In isolated TBI, coagulopathy may contribute to hemorrhagic lesion development, progression, or recurrence, as it may lead to a particular pattern of coagulopathy called TBI-induced coagulopathy (TBI-IC). We performed a retrospective and descriptive evaluation of 63 patients admitted to the Emergency Clinical Hospital Bucharest with the diagnosis of moderate/severe brain injury.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!